Basics Repligen Corporation Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. The company offers its products to life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. IPO Date: March 26, 1990 Sector: Healthcare Industry: Life Sciences Tools and Services Market Cap: $7.01B Activated in VL: True Average Daily Range Avg Daily Range: $1.18 | 2.14% Avg Daily Range (30 D): $2.53 | 2.13% Avg Daily Range (90 D): $2.34 | 1.88% Institutional Daily Volume Avg Daily Volume: .29M Avg Daily Volume (30 D): .69M Avg Daily Volume (90 D): .68M Trade Size Avg Trade Size (Sh.): 71 Avg Trade Size (Sh.) (30 D): 42 Avg Trade Size (Sh.) (90 D): 42 Institutional Trades Total Inst.Trades: 5,718 Avg Inst. Trade: $4.94M Avg Inst. Trade (30 D): $7.03M Avg Inst. Trade (90 D): $6.04M Avg Inst. Trade Volume: .05M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $7.03M Avg Closing Trade (30 D): $15.08M Avg Closing Trade (90 D): $12.62M Avg Closing Volume: 60.53K     News Feb 20, 2025 @ 4:25 PM Repligen's Q4 Slightly Tops Expectations Source: Jesterai Jan 9, 2025 @ 12:30 AM Chromatography System Market to Reach US$ 2.62 Bil... Source: Fact.Mr Dec 16, 2024 @ 1:11 PM BioLife Solutions Appoints Tony J. Hunt to its Boa... Source: Prnewswire Dec 12, 2024 @ 12:30 PM Repligen Announces Publication of the Companyâ€... Source: N/A Jun 26, 2024 @ 12:44 PM This Robinhood Analyst Turns Bullish; Here Are Top... Source: Avi Kapoor Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.25 $.26 $.1 Diluted EPS $-.25 $.26 $.1 Revenue $ 673.96M $ 182.37M $ 169.17M Gross Profit $ 298.23M $ 91.14M $ 90.76M Net Income / Loss $ -13.83M $ 14.87M $ 5.83M Operating Income / Loss $ -23.86M $ 13.9M $ 6.58M Cost of Revenue $ 375.73M $ 91.22M $ 78.42M Net Cash Flow $ -103.77M $ 10.64M $ -64.13M PE Ratio